Forbedret behandling af patienter med langvarig opioidbehandling til ikke-kræftsmerter i primærpleje (Opi-Prim)
Forbedret behandling af patienter med langvarig opioidbehandling til ikke-kræftsmerter i primærpleje (OPI-prim)
The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:
What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?
Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.
Participants will receive a person-centred team-based treatment consisting of:
- Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
- Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
- Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.
Primary objective:
To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care
Trial design and setting:
This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).
This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.
Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Magnus Peterson, PhD, MD
- Telefonnummer: +46702882768
- E-mail: magnus.peterson@regionuppsala.se
Undersøgelse Kontakt Backup
- Navn: Anna Svensson, MD
- Telefonnummer: +46702206400
- E-mail: anna.k.svensson@uu.se
Studiesteder
-
-
Gävleborg County
-
Gävle, Gävleborg County, Sverige
- Ikke rekrutterer endnu
- Region Gävleborg
-
Kontakt:
- Paul Dranichnikov, MD, PhD
- Telefonnummer: +46762175118
- E-mail: paul.dranichnikov@uu.se
-
-
Södermanland County
-
Strängnäs, Södermanland County, Sverige
- Ikke rekrutterer endnu
- Region Sörmland
-
Kontakt:
- Johanna Haraldsson, MD, PhD
- Telefonnummer: +46708636813
- E-mail: johanna.haraldsson@uu.se
-
-
Uppsala County
-
Uppsala, Uppsala County, Sverige
- Rekruttering
- Region Uppsala
-
Kontakt:
- Anna Svensson, MD
- Telefonnummer: +46702206400
- E-mail: anna.k.svensson@uu.se
-
-
Örebro County
-
Örebro, Örebro County, Sverige
- Rekruttering
- Region Örebro Län
-
Kontakt:
- Elsa Ekelin, MD
- Telefonnummer: +46708395260
- E-mail: elsa.ekelin@regionorebrolan.se
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Having received the equivalent of 90 days or more prescription of opioids for chronic pain made by the general practitioner during the recent 12 months
- Able to speak Swedish or English
Exclusion Criteria:
- Having been referred to a pain clinic (either at hospital or multimodal rehabilitation in primary care) within the last 6 months
- No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents informed consent.
- Using their opioids for cancer pain
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Ingen indgriben: Control
Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care. |
|
|
Aktiv komparator: Intervention
Phase 1 (investigation and assessment, week 1-3):
Phase 2 (treatment plan, week 3-4): - A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24):
|
Phase 1 (investigation and assessment, week 1-3):
Phase 2 (treatment plan, week 3-4): - A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24):
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain interference
Tidsramme: The primary outcome measure will be the difference in mean pain interference after 6 months.
|
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse. |
The primary outcome measure will be the difference in mean pain interference after 6 months.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain intensity
Tidsramme: After 3, 6 and 12 months
|
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 3-8. Scale: 0-10. Higher score is worse |
After 3, 6 and 12 months
|
|
Symptoms of depression
Tidsramme: After 3, 6 and 12 months
|
Measured with the Patient Health Questionnaire-9 (PHQ-9). Scale: 0-27. Higher score is worse |
After 3, 6 and 12 months
|
|
Symptoms of anxiety
Tidsramme: After 3, 6 and 12 months
|
Measured with the General Anxiety disorder-7 (GAD-7). Scale: 0-27. Higher score is worse |
After 3, 6 and 12 months
|
|
Patient satisfaction
Tidsramme: After 3, 6 and 12 months
|
Measured with the Patients´ Global impression of Change (PGIC). Scale: 0-6. Higher score is worse |
After 3, 6 and 12 months
|
|
Quality of life according to the 5-level EuroQol 5D
Tidsramme: After 3, 6 and 12 months
|
Measured with the 5-level EuroQol 5D (EQ-5D-5L). Scale: 1-5 per dimension. Higher score is worse. |
After 3, 6 and 12 months
|
|
Opioid use
Tidsramme: After 3, 6 and 12 months
|
Measured with as morphine equivalents: in mg. |
After 3, 6 and 12 months
|
|
Symptoms of withdrawal
Tidsramme: After 3, 6 and 12 months
|
Measured with the Short Opioid Withdrawal Scale (SOWS). Scale: 0-40. Higher score is worse |
After 3, 6 and 12 months
|
|
Pain interference
Tidsramme: After 3 and 12 months
|
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse. |
After 3 and 12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Opi-Prim
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .